Exploring the importance of inclusion criteria beyond the color of skin: Improvement in facial redness in skin of color subjects—An open-label, single center clinical study utilizing low molecular weight heparan sulfate

To the Editor: The awareness of skin of color (SOC) in dermatology is expanding; however, a lack of diversity in dermatologic clinical trials persists,1 especially considering the inclusion of African Americans/Blacks.2,3 This study provides evidence of how SOC can be excluded and/or underestimated for severity of symptoms because redness can be overlooked by visual examination. This open-label, single center clinical study assessing SOC using clinical grading and biophysical testing reveals the positive results and benefits of a daily regimen containing a patented low molecular weight heparan sulfate—heparan sulfate analog (HSA).